React4life’s Post

Last episode of the serie: the millifluidic paradigm. Let's meet starting from tomorrow at EUROoCS 2024. Discover our new HTS platform #Tokyo #Science #React4life

https://lnkd.in/dEqKRzVK 🧬💬 The Exosome Research Market, valued at US$ 183.04 Million in 2023, is projected to witness a robust growth at 12.15% CAGR through 2030, reaching nearly US$ 408.45 Million. Exosome research plays a pivotal role in exploring the vast landscape of intercellular communication. With a market size of 129.77 Million USD in 2021, ongoing efforts and research projects contribute to the remarkable growth of this market. Increasing research grants and projects from various organizations further propel advancements in understanding and leveraging the potential of exosomes. 🌐🔍 #stellarmarketresearch #ExosomeResearch #BiomedicalResearch #CellCommunication

🔍 Ever wondered how Point-of-Care in vitro diagnostics (PoC IVDs) revolutionise healthcare? They are medical tests and diagnostic procedures that are performed near or at the location where a patient is receiving care, rather than sending samples to a centralized laboratory for analysis. 🔬 🩺 The term "in vitro" means that the tests are conducted outside of the patient's body, typically using samples such as blood, saliva, etc. 🔗 Learn more here: https://lnkd.in/d7jZxxzZ #2dbiopadproject #horizoneurope #alzheimerdisease #innovation #graphene #nanomaterials #IVD #invitrodiagnostics Palacký University in Olomouc | Czech Advanced Technology and Research Institute | RCPTM - Regional Centre of Advanced Technologies and Materials | Q-PLAN INTERNATIONAL | Institut Català de Nanociència i Nanotecnologia (ICN2) | Grapheal | Aristotle University of Thessaloniki (AUTH) | NOVAPTECH | University of Eastern Finland | Alzheimer Hellas (Greek Association of Alzheimer’s Disease and Related Disorders) | Evnia | Central Institute of Mental Health | CeADAR Ireland | Graphene Flagship

🔬🌱 Unlocking the Potential of Biomedical Technologies in the Netherlands! Discover how the NXTGEN Hightech program is revolutionizing healthcare with Lab-on-Chip, Organ-on-Chip, and Cell Production Technology. 🚀 With a wealth of academic expertise in high-tech innovation, the Netherlands is paving the way for groundbreaking applications in biomedicine. Yet, translating this knowledge into real-world solutions remains a challenge. That's where project Biomed steps in! Led by LioniX, this initiative aims to bridge the gap between theory and practice by integrating chip production, cell technology, and bioactive materials. 🤝 🔍 Subprojects include: 🔬 One-Stop-Shop: Establishing a comprehensive biomedical production ecosystem. 🧪 Lab-on-Chip: Miniaturizing labs onto microchips for affordable diagnostics. 🧠 Organ-on-Chip: Scaling down organ systems for advanced drug discovery. 🔬 Cell Production Technology: Advancing cell culture for high-quality products. By fostering collaboration and innovation, the Netherlands is set to lead the global biomedical revolution. https://lnkd.in/dYdvUx2z #Biomedical #Innovation #NetherlandsTech #HealthcareRevolution #Photonics #PhotonicSpots LioniX International

🔬 Revolutionizing Antibody Discovery: HITMASTER - A Microfluidic Marvel 🔬 We're thrilled to share further details of our recent collaboration with VERAXA Biotech GmbH , pioneering groundbreaking advancements in antibody discovery. 🌟 This partnership represents a significant leap in medical research, employing microfluidic technology to screen millions of antibody-secreting cells with unprecedented precision and speed. 🚀 The result? An innovative microfluidic droplet sorting chip, ensuring each therapeutic candidate's purity and precision without the risk of contamination. 💧 Join us on this visionary journey as we bridge innovation with impact, shaping a future where every therapeutic potential is within our grasp. 💡 Partners involved in this project are temicon GmbH, Micronit, and JOANNEUM RESEARCH. Their invaluable contributions span from micro- and nanostructuring expertise to advanced microfluidic solutions and research innovation. Together, we're not just developing technology; we're crafting a synergy that accelerates the frontiers of scientific exploration and healthcare possibilities. 🤝🔬 👉 Dive into the details of our collaboration and the path-breaking technology on our blog: https://lnkd.in/did4-rNM #Microfluidics #Innovation #HealthcareTechnology #AntibodyDiscovery #Collaboration #FutureOfMedicine #ScientificCollaboration #MicroNanoTechnology #ResearchInnovation #MIHfamily This project is part of NextGenMicrofluidcs (https://lnkd.in/e7rsPRa). NextGenMicrofluidics has received funding from the European Union’s HORIZON 2020 research & innovation programme under grant agreement no. 862092.

⏰ Set your alarm for 17:15 today, so you do not miss Davide Carta's presentation "Engineering outer Blood Retinal Barrier on a chip to model pathological events in eye and study the effect of modulator drugs" at EUROoCS. Founded by Bi/ond and Dompé, Davide's PhD research show the potential that this innovative OoC model has to push forward retinal disease research and development of therapeutic methods for it. #euroooc #organonchip #inchipit #biomedicalresearch #microfluidics #gobiond

🚨🚨🚨News!! ICFO and VITALA Technologies awarded with more than 700K€ within the frame of a “Proyecto en colaboración público-privada 2022” The new project, called “SEE-13-MRI – Scope and Efficiency Extended 13C Magnetic Resonance Imaging", is funded as part of the “Proyecto de Colaboración Público-Privada 2022” by the Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación. The project will provide a two-fold approach to widen what clinicians and researchers are able to “see” using 13C MRI: VITALA will work on new routes to produce hyperpolarized tracer metabolites with long lifetimes, while ICFO will focus on techniques to continuously and non-destructively monitor their polarization using quantum sensors. Combining these technologies seek to widen access to early detection of disease and break barriers towards future commercial exploitation of HP-13C imaging in preclinical and clinical stages of drug discovery. The “Proyecto de Colaboración Público-Privada” program is part of the Spanish Research, Development and innovation program that is oriented to the challenges facing society. We celebrate this collaboration and hope to create solid results that create high value for the hyperpolarized field and drug testing community! Special thanks to Michael Tayler, Morgan Mitchell, Irene Marco-Rius Maria Alejandra Ortega Machuca Jose Luis Muñoz Gomez, and all their team members for making it possible and a special mention to our collaborators FI Group for managing the submission and office management in the project! #collaboration #startup #research #drugtesting #qualitycontrol #hyperpolarization

“The equivalent PXI-based instrument from NI (National Instruments) would be a bit larger and an order of magnitude more expensive, so I would recommend Moku:Lab to other engineers who have similar signal generation and acquisition requirements.” Learn how researchers at NanoCellect Biomedical, Inc. are using Moku:Lab to drive cell sorting innovation by enabling highly efficient digital synthesis with more accurate sweeps.

"The graveyard of healthcare innovation is completely full of solutions that all address unmet medical needs." 💡 Innovation in biotech requires not only solutions that address unmet needs but also a culture that encourages interdisciplinary thinking and risk-taking, as well as an environment and infrastructure conducive to entrepreneurship. In the latest episode of the podcast, I interviewed Prof. Dean Ho. He shared his experience of setting up a biotech company in Singapore and highlighted the ease of access to infrastructure, capital, and regulatory support. He believes that Singapore's ecosystem is uniquely positioned to drive rapid and rigorous validation and deployment of innovations. We also talked about what digital therapeutics entails and its promises for the future of medicine. For those interested in digital medicine do keep a look out for his book "Medicine without Meds" which comes out tomorrow (Oct 17) from Hopkins Press! https://lnkd.in/gbKWSiEG #biotech #clinicaltrial #innovation #digitalmedicine #startup #entrepreneurship #Singapore #digitaltherapeutics #AI #DTx, #healthcare

Researchers from SMART’s Critical Analytics for Manufacturing Personalized-medicine (CAMP) Interdisciplinary Research Group (IRG), in collaboration with Duke-NUS Medical School, the Institute of Molecular and Cell Biology (IMCB) at A*STAR - Agency for Science, Technology and Research, KK Women's and Children's Hospital, and Singapore General Hospital (SGH), have developed a groundbreaking method to produce clinical doses of viable autologous CAR T-cells. This innovative approach uses an ultra-small, automated, closed-system microfluidic chip about the size of a pack of cards, representing a breakthrough in efficiency as CAR T-cells can now be manufactured more easily and at a higher rate. This new method manufactures and expands CAR-T cells as effectively as traditional systems but with a smaller footprint, less space, fewer seeding cells, and reduced manufacturing reagents. This significant advancement could revolutionise autologous cell therapy production, making it more efficient and affordable. It has the potential to enable point-of-care manufacturing of CAR-T cells in hospitals and wards, inspiring a new era in personalised medicine. Learn more about this breakthrough in the blog post below. #SMARTMIT #CAMP #CancerTreatment #CARTCellTherapy #MedicalBreakthrough #Leukemia #Lymphoma #CellTherapy